Volume 4 Issue 1
Jun.  2020
Turn off MathJax
Article Contents
Yun Ye, Xiaohua Yuan, Jianjun Wang, Yuchen Wang, Suliang Li. The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis[J]. Blood&Genomics, 2020, 4(1): 53-60. doi: 10.46701/BG2020012019131
Citation: Yun Ye, Xiaohua Yuan, Jianjun Wang, Yuchen Wang, Suliang Li. The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis[J]. Blood&Genomics, 2020, 4(1): 53-60. doi: 10.46701/BG2020012019131

The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis

doi: 10.46701/BG2020012019131
More Information
  • Corresponding author: Suliang Li, Department of Laboratory Medicine, the First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China. E-mail: lisuliang01@163.com
  • Received Date: 2019-12-09
  • Accepted Date: 2020-01-31
  • Rev Recd Date: 2020-01-07
  • Available Online: 2021-07-01
  • Publish Date: 2020-06-30
  • MiR-141 has gradually demonstrated its value in the diagnosis of prostate cancer. However, the diagnostic parameters applied in previous studies were different. This systematic review was conducted to explore the diagnostic value of miR-141 in prostate cancer. A comprehensive search of related literature in PubMed, Medline, the Cochrane Library and Embase databases was performed. Seven studies were included which assessed the diagnostic value of miR-141 in patients with prostate cancer up to October 31, 2019. Meta-disc version 1.4 and STATA software version 12.0 were used to analyze the data. The pooled sensitivity and specificity were 0.70 (95% CI 0.64~0.75) and 0.73 (95% CI 0.64~0.80), respectively. The positive likelihood ratio (PLR) was 2.88 (95% CI 1.40~5.93), and negative likelihood ratio (NLR) was 0.38 (95% CI 0.20~0.71). The pooled diagnostic odds ratio (DOR) of miR-141 for prostate cancer was observed to be 9.94 (95% CI: 2.55~38.80). The summary area under the receiver operating characteristic (ROC) curve was 0.83 (95% CI: 0.79~0.86). The results of meta-regression suggested that heterogeneity was mainly derived from patient age. The Fagan nomogram results showed a significant increase when correlating miR-141 with the diagnosis of prostate cancer. This meta-analysis suggests that miR-141 has a high diagnostic value for prostate cancer. In future, large-scale prospective studies will be done to verify and evaluate this result.

     

  • Conflict of interests: The authors declare that there are no conflicts of competing interests.
  • loading
  • [1]
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-917. doi: 10.1002/ijc.25516
    [2]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
    [3]
    Wang Y, Guo J, Xu L, et al. Should bone scan be performed in Chinese prostate cancer patients at the time of diagnosis?[J]. Urol Int, 2013, 91(2): 160-4. doi: 10.1159/000348330
    [4]
    Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight?[J]. Rev Urol, 2013, 15(3): 97-107. http://europepmc.org/abstract/med/24223021
    [5]
    Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay[J]. Nat Rev Genet, 2010, 11(9): 597-610. doi: 10.1038/nrg2843
    [6]
    Song CJ, Chen H, Chen LZ, et al. The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies[J]. J Cell Biochem, 2018, 119(3): 2763-86. doi: 10.1002/jcb.26445
    [7]
    Chen M, Calin GA, Meng QH. Circulating microRNAs as promising tumor biomarkers[J]. Adv Clin Chem, 2014, 67: 189-214. http://www.ncbi.nlm.nih.gov/pubmed/25735862
    [8]
    Peng J, Xie Z, Cheng L, et al. Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer[J]. BMC Cancer, 2015, 15: 158. doi: 10.1186/s12885-015-1123-2
    [9]
    Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043): 834-8. doi: 10.1038/nature03702
    [10]
    Mishra S, Deng JJ, Gowda PS, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor Ⅱ (TGFBR2) expression in prostate cancer[J]. Oncogene, 2014, 33(31): 4097-106. doi: 10.1038/onc.2013.374
    [11]
    Ghorbanmehr N, Gharbi S, Korsching E, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer[J]. Prostate, 2019, 79(1): 88-95. doi: 10.1002/pros.23714
    [12]
    Song CJ, Chen H, Chen LZ, et al. The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies[J]. J Cell Biochem, 2018, 119(3): 2763-86. doi: 10.1002/jcb.26445
    [13]
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement[J]. PLoS Med, 2009, 6: e1000097. doi: 10.1371/journal.pmed.1000097
    [14]
    Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies[J]. BMC Med Res Methodol, 2006, 6: 9. doi: 10.1186/1471-2288-6-9
    [15]
    DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986, 7(3): 177-88. doi: 10.1016/0197-2456(86)90046-2
    [16]
    Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data[J]. Stat Med, 2002, 21(9): 1237-56. doi: 10.1002/sim.1099
    [17]
    Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses[J]. Stat Med, 2012, 31(29): 3805-20. doi: 10.1002/sim.5453
    [18]
    Altman DG, Bland JM. Interaction revisited: the difference between two estimates[J]. BMJ, 2003, 326: 219. doi: 10.1136/bmj.326.7382.219
    [19]
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed[J]. J Clin Epidemiol, 2005, 58: 882. doi: 10.1016/j.jclinepi.2005.01.016
    [20]
    Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice[J]. Acta Paediatr, 2007, 96(4): 487-91. doi: 10.1111/j.1651-2227.2006.00179.x
    [21]
    Porzycki P, Ciszkowicz E, Semik M, et al. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition[J]. Int Urol Nephrol, 2018, 50(9): 1619-26. doi: 10.1007/s11255-018-1938-2
    [22]
    Kachakova D, Mitkova A, Popov E, et al. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer[J]. DNA Cell Biol, 2015, 34(3): 189-200. doi: 10.1089/dna.2014.2663
    [23]
    Haldrup C, Kosaka N, Ochiya T, et al. Profiling of circulating microRNAs for prostate cancer biomarker discovery[J]. Drug Deliv Transl Res, 2014, 4(1): 19-30. doi: 10.1007/s13346-013-0169-4
    [24]
    Kelly BD, Miller N, Sweeney KJ, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group[J]. J Clin Med, 2015, 4(7): 1369-79. doi: 10.3390/jcm4071369
    [25]
    Li Z, Ma YY, Wang J, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients[J]. Onco Targets Ther, 2015, 9: 139-48. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706124/
    [26]
    Ghorbanmehr N, Gharbi S, Korsching E, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer[J]. Prostate, 2019, 79(1): 88-95. doi: 10.1002/pros.23714
    [27]
    Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer[J]. Tumour Biol, 2011, 32(3): 583-8. doi: 10.1007/s13277-011-0154-9
    [28]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
    [29]
    Lima AR, Pinto J, Azevedo AI, et al. Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine[J]. Br J Cancer, 2019, doi: 10.1038/s41416-019-0585-4.
    [30]
    Szeliski K, Adamowicz J, Gastecka A, et al. Modern urology perspectives on prostate cancer biomarkers[J]. Cent European J Urol, 2018, 71(4): 420-6.
    [31]
    Yin C, Fang C, Weng H, et al. Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis[J]. Int Urol Nephrol, 2016, 48(7): 1087-95. doi: 10.1007/s11255-016-1281-4
    [32]
    Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci USA, 2008, 105(30): 10513-8. doi: 10.1073/pnas.0804549105
    [33]
    Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells[J]. Proc Natl Acad Sci USA, 2007, 104(50): 19983-8. doi: 10.1073/pnas.0706641104
    [34]
    Li SL, Ye Y, Wang SY, et al. Exosomal miR-375 promotes the activity of osteoblasts in prostate cancer[J]. Asia-Pacific Journal of Blood Types and Genes, 2018, 2(4): 241-8. http://www.researchgate.net/publication/342811642_Exosomal_miR-375_promotes_the_activity_of_osteoblasts_in_prostate_cancer
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(2)

    Article Metrics

    Article views (15) PDF downloads(0) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return